Endocrine and Hormonal Disorders for APRNs Part 2: Hypopituitarism and Other Hormone Deficiencies NursingCE Course

3.0 ANCC Contact Hours AACN Category A

Objectives: Upon completion of this CE activity, the APRN will be able to do the following:

  • Describe the statistical data regarding endocrine disorders in the US, including prevalence and significance 
  • Articulate the pathophysiology, risk factors, clinical presentation, diagnostic workup, evidence-based management, and potential complications of hypothalamus and pituitary disorders, including hypopituitarism, growth hormone deficiency, diabetes insipidus (DI), and central hypothyroidism
  • Define the pathophysiology, risk factors, clinical presentation, diagnostic workup, evidence-based management, and potential complications of gonadotropic dysfunction, including primary hypogonadism (e.g., primary ovarian insufficiency [POI], delayed puberty) and secondary hypogonadism (e.g., functional hypothalamic amenorrhea, central hypogonadism)

The purpose of this module is to provide the APRN with an overview of the pathophysiology, risk factors, clinical presentation, diagnostic workup, evidence-based management guidelines, and potential complications of primary endocrine disorders leading to hormonal deficiencies, including hypothalamus and pituitary disorders, growth hormone deficiency, DI, hypothyroidism, and hypogonadism. Please see the first part of this endocrine series for a review of the anatomy and physiology of the endocrine system (Figure 1).

There are many disorders of the endocrine system, and an imbalance or disorder of one part of the endocrine system can lead to disorders within other parts. Identifying the primary etiology of the disorder is vital in determining the optimal treatment. Primary endocrine disorders originate within the gland, while secondary endocrine disorders result from problems outside of the glands, typically within the feedback mechanism. External problems may be due to trauma, surgery, infection, tumors, or certain drugs. Causes of endocrine disorders vary but often involve either an excess or deficiency in hormone secretion or insensitivity of the target tissue to the hormone (Hopper, 2015; Ignatavicius et al., 2018). 

Hypothalamic/Pituitary Disorders

Hypopituitarism

Hypopituitarism occurs when dysfunction of the pituitary gland, the hypothalamus, or the surrounding structures leads to a deficiency in pituitary hormone production. Panhypopituitarism or complete hypopituitarism happens when all the pituitary hormones are affected. When only one or more pituitary hormones are involved, the syndrome is called isolated or partial hypopituitarism (Corenblum, 2020). This rare disorder affects between 29 and 45 people in every 100,000 with an annual incidence of roughly 4.2 of 100,000; both sexes are affected equally (Snyder, 2019a). Hypopituitarism can create low levels of growth hormone (GH), antidiuretic hormone (ADH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), or the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH; Fleseriu et al., 2016). Hypopituitarism in children can lead to short stature (i.e., dwarfism) or delayed puberty. The prognosis is good with early recognition and prompt treatment to correct the underlying cause (Corenblum, 2020).  

Pathophysiology. Hypopituitarism leads to the altered production of hormones that are formed or stored in the pituitary. This includes the anterior pituitary hormones (TSH, FSH, LH, GH, ACTH, and prolactin [PRL]) and the posterior pituitary hormones (ADH and oxytocin). Rarely, pituitary disease can affect the production of ADH; more commonly, hypothalamic conditions may cause ADH deficiency resulting in diabetes insipidus (DI). Hypopituitarism is more likely to prompt a deficiency of GH or gonadotropins and less likely to lead to ACTH or TSH deficiency. Pituitary tumors or adenomas are the most common cause of primary hypopituitarism in adults, responsible for roughly 40-60%; this condition can also be caused by:

  • traumatic brain injuries (TBIs);
  • radiation therapy;
  • chemical agents;
  • hypophysitis (inflammation of the pituitary that is lymphocytic, granulomatous, plasmacytic, xanthomatous, or secondary to immunotherapy drugs such as ipilimumab [Yervoy]);
  • pituitary infarct or apoplexy (hemorrhage);
  • infections such as meningitis, tuberculosis, and syphilis or abscess;
  • hereditary hemochromatosis with gonadotropin deficit;
  • surgical procedures to excise pituitary adenomas;
  • pituitary stalk interruption syndrome; and
  • empty sella (an enlarged sella turcica not entirely filled with pituitary tissue; Corenblum, 2020; Snyder, 2019a). 

In children, hypopituitarism may be related to congenital defects or underlying conditions such as an autoimmune process or infection. Secondary hypopituitarism is a deficiency in the releasing hormone(s) that are produced by the hypothalamus; it is often due to tumor but may also be secondary to radiation therapy, infiltrative disease (sarcoidosis), infection (meningitis due to tuberculosis, candida, or viruses in those with immunocompromise), TBI, or stroke (Corenblum, 2020; Snyder, 2019a).

Clinical Presentation. APRNs should recognize the signs and symptoms of pituitary pathology—particularly those that may be life-threatening—and initiate treatment promptly (Society for Endocrinology, 2018).  Depending on the etiology, onset, and extent of hormone involvement, patients with hypopituitarism can have variable clinical presentations ranging from asymptomatic to acute cardiopulmonary collapse. Pituitary apoplexy is a medical emergency most commonly caused by bleeding into or the death of an area of tissue within the pituitary gland, typically related to a pituitary tumor. The signs of pituitary apoplexy are as follows:

  • severe and sudden-onset headache (HA)
  • nausea and vomiting
  • paralysis impacting eye movement
  • visual impairment such as double vision 
  • decreased consciousness (Society for Endocrinology, 2018)

Panhypopituitarism can cause several physiological, psychological, and mental problems that include:

  • orthostatic hypotension
  • bradycardia
  • lethargy
  • psychosis
  • anorexia
  • anemia (Willis, 2019)

Patients with hypopituitarism caused by infection or surgery typically present with fevers, hypotension, vomiting, and hypoglycemia. In contrast, pituitary tumors characteristically cause HAs, visual disturbances that could lead to blindness, or hemianopia (blindness over half the visual field). Since hypopituitarism symptoms are not apparent until up to 75% of the pituitary gland is destroyed or not functioning, patients may not recognize or report any problems initially. APRNs should be meticulous with their assessments to facilitate early recognition and reduce morbidity and mortality (Corenblum, 2020; Willis, 2019). 

  • Early signs of panhypopituitarism may include hypogonadism due to diminished FSH or LH levels, termed secondary hypogonadism or hypogonadotropic hypogonadism. The clinical presentation, diagnostic process, and management guidelines for most of the hormones will be discussed in the corresponding sections below, as the symptoms and treatments mirror those for other causes of hormone deficiency. Gonadotropin and GH deficiency are more common than ACTH or TSH deficiency. A decreased TSH level causes secondary hypothyroidism. Ultimately, adrenocorticotropic failure (decreased corticotrophin levels) leads to adrenal insufficiency, which is discussed in detail in a separate course, Endocrine and Hormonal Disorders Part 4: Adrenal Gland Disorders. Acute adrenal insufficiency may initially create a life-threatening adrenal crisis, which requires immediate medical intervention. Isolated PRL deficit is rare, and most patients have evidence of other hormonal deficit(s); this condition would present with an inability to lactate (Corenblum, 2020, Snyder, 2020a). 

Diagnosis. The decision to test a patient for hypopituitarism should be based on the presence of symptoms of a hormonal deficit or a lesion that commonly causes hypopituitarism (Snyder, 2020b). Diagnostic laboratory testing includes an evaluation of baseline levels of the pituitary hormones and those produced by target glands via radioimmunoassay (Fleseriu et al., 2016). Specific tests and reference ranges will be detailed for each hormone in the corresponding sections below. Of note, PRL deficiency is not often tested for, as it is difficult to distinguish between low and normal levels, and there is no standard test for reserve (Snyder, 2020b).

In addition to laboratory screening, diagnostic tests such as computerized tomography (CT) or magnetic resonance imaging (MRI) can help visualize the hypothalamus, pituitary, and surrounding structures for the presence of a mass or lesion. Visual fields should be assessed if a pituitary mass is found to be the cause of hypopituitarism (Corenblum, 2020; Gouden & Jialal, 2020). 

Treatment. Since hypopituitarism is a complex medical condition, it is best managed by an interprofessional team consisting of a neurosurgeon, an endocrinologist, a pathologist, a radiologist, a primary health care provider (HCP), and an ophthalmologist. Weight should be monitored closely, and a dietary consult should be considered for patients with anorexia or weight fluctuations. Parents of children with GH deficiency should be offered a referral to mental health counseling due to the associated stress for the patient and their parents (Fleseriu et al., 2016; Gounden & Jialal, 2020).

Treatment for hypopituitarism includes the replacement of the hormones that are secreted by the target glands. If left untreated, the loss of all anterior pituitary hormone function is fatal. Treatment should also focus on the management of the underlying cause, which may include the surgical removal of a tumor (Mayo Clinic, 2019b). As previously noted, since PRL deficiency is exceedingly rare, it is not routinely part of screenings. Clinical manifestations include an inability to lactate (Snyder, 2020a). There is currently no commercially available PRL replacement product in the US. A single open-label pilot study (n=5) testing human recombinant PRL (r-hPRL) given subcutaneously (SQ) every 12 hours for 28 days increased participants mean milk production from 3.4 to 66.1 mL/day (Snyder, 2019c, 2020b).

The APRN should ensure patients with hypopituitarism receive adequate education that is inclusive of the following points:

  • instruct the patient to wear a medical bracelet consistently identifying their disorder;
  • emphasize the importance of life-long hormone replacement therapy and ensure the patient understands their medication regime, including prescription medications, herbals, and over-the-counter (OTC) drugs that may interact with their hormone therapies; and
  • reinforce the importance of routine monitoring of hormone levels to maintain therapeutic levels and avoid excess or inadequate replacement (Gounden & Jialal, 2020). 

Complications. Long-term complications include an increase in all of the following: 

  • mortality rates in those with nonfunctioning pituitary adenomas and deficiencies in ACTH or gonadotropin,
  • the risk of cardiovascular disease due to decreased high-density lipoprotein (HDL) cholesterol levels and elevated low-density lipoprotein (LDL)/HDL ratio, and
  • the incidence of cerebrovascular morbidity and mortality following pituitary radiotherapy (Corenblum, 2020; Willis, 2019). 

The focus of this module will now shift to describe the presentation, diagnosis, and treatment of three common forms of hypopituitarism: GH deficiency, DI caused by ADH deficiency, and central/secondary hypothyroidism. We will then outline the various forms of hypogonadism, including secondary hypogonadism. Secondary adrenal insufficiency will be discussed in the previously mentioned course on adrenal dysfunction (Snyder, 2020a).

Growth Hormone Deficiency

GH (or somatotropin) is produced by somatotrophs in the anterior pituitary in response to the secretion of GH-releasing hormone (GHRH) by the hypothalamus. The production of GH by the pituitary is inhibited by the secretion of somatostatin (Chapman, 2019). The majority of GH is free/circulating, while approximately 40% is bound by GH-binding proteins (GHBP). It binds to GH receptors to facilitate growth and increased metabolism. The release of GH stimulates the production of insulin-like growth factor (IGF-1) by the liver, which thereby facilitates GH’s growth-promoting effects on the human skeleton (bone and cartilage tissue; El Sayed et al., 2020). GH deficiency presents differently in adults versus children (Snyder, 2020c). GH deficiency typically leads to a decreased lean-to-fat body mass, osteopenia, and in some cases, hyperlipidemia, cardiovascular disease, emotional changes (e.g., dysphoria, lethargy), and increased mortality in adults. In children, GH deficiency leads to short stature, as evidenced by decreased growth velocity and potentially delayed puberty (Corenblum, 2020; Snyder, 2020a).

Pathophysiology. The vast majority (75%) of cases of GH deficiency in adults result from a pituitary tumor or are secondary to the treatment of a pituitary tumor (Snyder, 2020c). Children with a deficiency in GH may present with proportionate dwarfism, in which the head, trunk, and limbs are small but proportionate to each other. The term dwarfism may be considered insensitive or offensive, and health care providers should consider using the term “short stature” instead, displaying abundant sensitivity to the emotional and psychological issues related to the condition (Mayo Clinic, 2018, 2019b). 

Short stature secondary to hypopituitarism is often not recognized at birth; however, the early symptoms typically appear within the first months of life and are recognizable by six months, allowing early intervention. Children with short stature may appear overweight due to adipose tissue deposits in their lower trunk. They may have delayed secondary tooth eruption. The long-term outcome for an affected child will depend on the timing of disease presentation, diagnosis, and intervention for hypopituitarism. If the disease develops before puberty, secondary sex characteristics may be delayed or prevented (Willis, 2019). 

Diagnosis. Children whose height is at least 2.5 standard deviations below the mean for their age or weight should be evaluated for GH deficiency. This includes children with a decrease in their height curve across two major height percentage curves (e.g., the child was above the 25th percentile and subsequently falls to below the 10th). The differential diagnoses for GH deficiency in a child include systemic disease, hypothyroidism, Turner syndrome, and various skeletal disorders (Richmond & Rogol, 2020a). Adult patients at increased risk include those with known pituitary or hypothalamus disease, deficiencies in other pituitary hormones, or a history of GH deficiency. Prior to testing, the provider should carefully consider the utility, risks, and benefits of identifying a GH deficiency in an adult patient, as the treatment for GH deficiency in adults is often not advisable or affordable, especially for those with adult-onset disease (Snyder, 2020c). 

IGF-1 is the primary diagnostic laboratory test for GH deficiency. In children under the age of 3 years, IGF binding protein-3 (IGFBP-3) may be a more effective diagnostic indicator. If both of these levels are within their respective reference ranges, no further testing is required. A bone age assessment is also recommended for young children with suspected GH deficiency. Bone age is typically calculated using a simple radiograph of the patient’s left hand or wrist. This radiograph is analyzed using standard methods, most often the Greulich and Pyle Atlas or the Tanner-Whitehouse 3 method, to determine the patient’s skeletal age. If both IGF-1 and IGFBP-3 are low and the patient’s bone age is delayed, provocative testing may confirm the diagnosis, although this may not be necessary in the context of severe growth failure (Richmond & Rogol, 2020a, 2020b). IGF-1 levels are also used to evaluate adult patients with suspected GH deficiency, as GH levels drop in healthy adults during the day, and a single level cannot determine a deficiency. An IGF-1 level below normal in an adult patient with organic pituitary disease is diagnostic. 

Provocative testing for both children and adult patients with equivocal test results using arginine, clonidine, glucagon, or an insulin bolus can be considered for confirmation if required. While the use of an insulin bolus is highly accurate, the risks are substantial. For this reason, provocative testing after an overnight fast using glucagon, arginine and GHRH (not currently available in the US), or macimorelin (Macrilen) is currently recommended. A substandard GH response to provocative testing confirms the diagnosis of GH deficiency. Obesity impairs GH release, so the diagnostic cutoff should be adjusted downward in patients with obesity (Snyder, 2020c; Willis, 2019). In children, provocative testing should be done using 5 µg/kg (max 250 µg) of clonidine, arginine at 0.5 g/kg (max 40 g) intravenously (IV), or glucagon at 0.03 mg/kg (max 1 mg) SQ. Serial GH levels are then drawn for 1.5 to 3 hours after medication administration. Patients receiving clonidine should be monitored for hypotension and hypoglycemia, while glucagon may cause nausea, vomiting, HA, or diaphoresis. Macimorelin (Macrilen) has not been appropriately tested or approved for use in pediatric patients. If GH levels increase significantly despite low levels of IGF/IGFBP-3 in the context of a child with short stature, the provider should consider GH insensitivity (Richmond & Rogol, 2020a). In adults, provocative testing can be done using 0.5 mg/kg macimorelin (Macrilen) or 1 mg glucagon IM. Macimorelin (Macrilen) is often preferred due to its convenient oral administration and low incidence of adverse effects, although it may cause dysgeusia (altered taste) and QT prolongation (Snyder, 2020c). Imaging studies, specifically an MRI of the brain focused on the area surrounding the pituitary and hypothalamus, should be considered for those with GH deficiency. The APRN should consider laboratory testing to rule out other hormonal deficiencies, such as cortisol, ACTH, LH, FSH, TSH, and/or PRL (Richmond & Rogol, 2020b).

Treatment. In children, most experts recommend treatment with recombinant human GH, or somatropin (rhGH, Omnitrope, Norditropin, Humatrope, Genotropin), if the epiphyses are open. Dosing should start at 20-35 µg/kg SQ daily. In cases of severe deficiency, dosing may have to be started lower than this value. IGF-1 levels should be reassessed 4 weeks after initiating treatment, following any dose changes, and every 6-12 months once dosing is stable. Height should be reassessed at 3- to 6-month intervals toward a goal of 75th percentile for growth velocity. Treatment should continue until linear growth is nearly complete (height velocity under 2 or 2.5 cm/year). At that point, tests can be repeated to determine if treatment should continue into adulthood. Children with isolated GH deficiency often do not require treatment as adults, whereas children with genetic or organic forms of GH deficiency, panhypopituitarism, or structural abnormalities of the pituitary or hypothalamus require ongoing treatment. In older children and adolescents, a gonadotropin-releasing hormone (GnRH) agonist (an aromatase inhibitor such as letrozole [Femara] or anastrozole [Arimidex]) may help delay epiphyseal closure, but this has not been well-tested with regard to safety or efficacy (Rogol & Richmond, 2020). The long-term outcomes for children with GH deficiency depend on the timing of disease presentation, diagnosis, and intervention for hypopituitarism. If the disease develops before puberty, secondary sex characteristics may be delayed or prevented (Willis, 2019). Ideally, treatment may help patients achieve a normal height and increase their musculature (Cleveland Clinic, 2020).

The 2016 Endocrine Society guidelines regarding hypopituitarism in adults recommend the use of somatropin (Omnitrope) in most adults, although many experts question whether the limited clinical benefit of this treatment outweighs the high cost of this medication. Treatment aims to increase muscle mass, decrease fat mass, improve cardiac function, and potentially improve bone mineral density (BMD) and quality of life. Studies indicate that treatment of adults does not lead to improved energy. For this reason, treatment is not indicated for most adult patients unless they present with a history of childhood-onset GH deficiency and the specific risk factors mentioned above. Somatropin (Omnitrope) is typically administered at a dose of 5 µg/kg SQ, but dosing should be initiated at 2-5 µg/kg and then adjusted every 2 months to achieve an IGF-1 in the middle of the reference range. Side effects of somatropin (Omnitrope) include peripheral edema, arthralgia, carpal tunnel syndrome, paresthesias, and glucose intolerance. Rarely, it can lead to benign intracranial hypertension, macular edema, proliferative retinopathy, or second neoplasms in those with a history of childhood malignancy. Its use is contraindicated in those with active malignancy (Snyder, 2020c). Of note, the correction of GH deficiency without first or concurrently correcting adrenal insufficiency may incite a life-threatening adrenal crisis (Nieman, 2020).

Diabetes Insipidus 

DI is an uncommon disorder that results in fluid imbalances in the body, causing polyuria and polydipsia. It can be caused by an ADH deficiency related to a tumor, trauma, or other problem within the hypothalamus or pituitary gland. In addition, surgeries in the area of the pituitary, certain drugs such as glucocorticoids, or alcohol can result in DI (Hopper, 2015; Mayo Clinic, 2019a). There are multiple types of DI, as shown in Table 1 below. 

The estimated prevalence of central DI is 1 per 25,000 people (Shahid et al., 2020). Risk factors for all types of DI consist of anything that damages the hypothalamus or pituitary, including surgery, head injury, infection, inflammation, increased intracranial pressure (ICP), or a tumor (Mayo Clinic, 2019a; NIDDK, 2015).

Pathophysiology. ADH is synthesized in the hypothalamus and stored and secreted by the posterior pituitary; it manages the reabsorption of water by the distal tubules and collecting ducts in the kidneys. ADH deficiency leads to excessive diuresis. With all types of DI, patients can urinate from 3-15 L per day. Other signs and symptoms include dry skin, polydipsia (increased thirst), fatigue, dizziness, confusion, and nausea (NIDDK, 2015). This diuresis leads to dehydration, increased serum osmolality (concentrated blood), and hypotension. Increased serum osmolality prompts polydipsia, which typically causes some patients to drink enough fluids to maintain fluid balance, at least initially. If the patient is unconscious or has a defective thirst mechanism, dehydration can occur quickly (Hopper, 2015; Mayo Clinic, 2019a; NIDDK, 2015).

Diagnosis. The diagnosis of DI is initially based on a history of risk factors and symptoms. Infants may present with irritability, crying, weight loss or poor growth, and hyperthermia. Children may report fatigue and exhibit anorexia, enuresis, and a linear growth defect. Adults may have hydronephrosis and/or bladder enlargement on physical examination. The differential diagnoses that should also be considered include the following:

  • histiocytosis
  • hypercalcemia
  • hypokalemia
  • medullary cystic disease
  • pediatric abusive head trauma
  • type 1 diabetes mellitus (T1DM) 
  • sickle cell anemia (Khardori, 2020)

A urinalysis should be performed to assess urine specific gravity and glucose to rule out DM; patients with DI will typically have a specific gravity that is below 1.001 (reference range: 1.001-1.029; Hopper, 2015). A 24-hour urine is typically ordered to assess urine osmolality and specific gravity, as well as tests for serum electrolytes, glucose, osmolality, and sometimes ADH. A urine specific gravity below 1.005, a urine osmolality below 200 mOsm/kg, and a plasma osmolality above 287 mOsm/kg are diagnostic for central DI (Khardori, 2020). ADH can also be measured in plasma or urine after the administration of hypertonic saline or fluid restriction. In healthy individuals, the ADH level will rise; if not, DI is suspected (Hopper, 2015).

If further confirmation is required, a water deprivation (i.e., Miller-Moses) test may be done. This involves depriving the patient of water for up to 6 hours while assessing body weight and osmolality hourly. DI is suspected if the urine continues to be diluted and the patient experiences over 3% weight loss. Then, 5 units of ADH SQ are given with a final urine osmolality check an hour later. In central DI, this injection should correlate with an improvement in osmolality (urine output increases from below 300 mOsm/kg before the ADH injection to above 750 mOsm/kg after) and polyuria. A patient with primary polydipsia will maintain a urine osmolality of greater than 750 mOsm/kg throughout the fluid deprivation testing (Khardori, 2020). In addition to the water deprivation test, an MRI should be ordered to assess for any abnormalities around the hypothalamus or pituitary gland. Often, the hyperintense signal within the posterior pituitary on T1-weighted images in healthy patients is absent in central DI (Khardori, 2020). Genetic screening may be recommended for patients with a family history of polyuria (Mayo Clinic, 2019a). 

Treatment. Treatment will vary according to the type of DI. For severe cases requiring hospitalization, hypotonic IV fluids (i.e., 0.45% normal saline [NS]) should be used to replace intravascular volume without adding sodium. For mild DI, the patient may only need to increase their water intake, especially if the thirst mechanism remains intact. Underlying structural abnormalities, such as tumors in the hypothalamus or pituitary, may be corrected surgically. The primary medication used for the maintenance treatment of central and gestational DI is desmopressin (DDAVP, Stimate), a synthetic analog, to replace the missing ADH and decrease urination. It is available SQ or IV, as well as an intranasal spray and an oral tablet. It is dosed BID/TID, and medication initiation or significant dose adjustments may require hospital admission for monitoring of electrolytes, 24-hour urine collection, specific gravity, fluid intake, frequency and volume of urine, and reports of thirst (NIDDK, 2015). The initial dosing is typically weight-based, starting at 0.05 mg (5 µg) PO BID. The maximum dosage is 1.2 mg/day. This medication can be expensive. Patients should be educated regarding common adverse effects, including flushing, HA, rhinitis, nausea, abdominal pain, dizziness, and hyponatremia. Once dosing has stabilized, the patient should complete follow-up visits every 6-12 months (Khardori, 2020).

A low-protein and low-sodium diet may also help reduce urine output. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (Indocin) may reduce urinary output and raise urinary osmolality in patients with nephrogenic DI by inhibiting prostaglandin synthesis in the kidney, thereby enhancing the ability of ADH to concentrate urine. Patients with primary polydipsia should be encouraged to reduce their fluid intake, and any underlying mental illness should be assessed and optimally managed. Chlorpropamide (Diabinese) is a sulfonylurea that may be used off-label for vasopressin-sensitive (non-nephrogenic) DI as an alternative to DDAVP. Diuretics such as hydrochlorothiazide (HCTZ) may also be used off-label (Hopper, 2015; Khardori, 2020; Mayo Clinic, 2019a).

Central Hypothyroidism

Thyroid disease (see Figure 2) is generally characterized as overactive (hyperthyroidism) or underactive (hypothyroidism) functioning. Hypothyroidism is classified as primary or secondary; the primary form is much more common. Secondary, or central, hypothyroidism is caused by the failure of the pituitary gland or hypothalamic disease, as the body does not make adequate amounts of TRH/TSH to stimulate the release of T3/4 (see Figure 3). This occurs in approximately 1 in 20,000 to 80,000 people (Ross, 2019a; Shahid et al., 2020). For additional information regarding the pathophysiology, underlying epidemiology, presentation, diagnosis, and management of primary hypothyroidism, explore the NursingCE activity entitled Thyroid Dysfunction, available on NursingCE.com. 

Pathophysiology. Secondary hypothyroidism is caused by a failure to stimulate normal thyroid function and not the thyroid itself. Secondary hypothyroidism occurs due to hypothalamus or pituitary disease or trauma, resulting in diminished TRH or TSH secretion (American Thyroid Association [ATA], n.d.a). Central hypothyroidism may also be associated with ADH, oxytocin, PRL, FSH, LH, GH, and ACTH deficiencies (Duke Health, 2018). It may result from a tumor, infection, infarction, or TBI causing damage to the hypothalamus or pituitary gland. Iatrogenic causes involve pituitary/hypothalamus function, such as previous radiation therapy or surgical trauma (Ross, 2019a; Shahid et al., 2020). 

Regardless of the cause, if the thyroid gland does not produce enough thyroid hormone, all mental and physical processes slow down. The thyroid manages metabolism, and a slowed metabolic rate is responsible for many of the characteristic symptoms. Furthermore, cellular functions are diminished, reducing oxygen consumption, oxidation of nutrients for energy, and body heat (ATA, n.d.a). 

Diagnosis. Symptoms of central hypothyroidism resemble those of primary hypothyroidism—such as fatigue, cold intolerance, muscle cramps, HA, and weight gain—but may be less pronounced (Ross, 2019a). In children, central hypothyroidism may reduce growth velocity (Shahid et al., 2020). Recognizing the signs and symptoms of hypothyroidism can be difficult as they may be vague and nonspecific: for example, extreme fatigue is often the first symptom reported by those suffering from hypothyroidism (ATA, n.d.a). Other symptoms of hypothyroidism in adult patients can include:

  • bradycardia
  • constipation 
  • mental dullness
  • shortness of breath
  • decreased perspiration
  • facial edema (especially periocular)
  • joint pain
  • hair thinning or loss
  • dry skin and hair 
  • sexual dysfunction such as menstrual irregularities/amenorrhea (Hopper, 2015)

There are no universal recommendations for screening of thyroid disease in adults, but the ATA suggests screening at 35 years of age and every 5 years thereafter, particularly in high-risk patients, which include:

  • pregnant women,
  • women over 60 years of age,
  • patients with autoimmune disease such as T1DM,
  • patients with a history of radiation of the neck or brain,
  • patients with other hypothalamus or pituitary hormone deficiencies, and
  • patients with a prior history of TBI or pituitary/hypothalamus surgery (Orlander, 2019; Ross, 2019a).

In addition to the history and physical examination, a serum TSH level should be performed to establish a diagnosis of central hypothyroidism. According to the US Preventive Services Task Force (2015), TSH is considered the first-line screening test for patients with suspected thyroid dysfunction. The level of circulating TSH in the blood helps determine if the thyroid is functioning normally, overactive, or underactive. If TSH is high, the thyroid gland is not producing enough T3/T4, which would raise the clinical suspicion for primary hypothyroidism. Conversely, if the TSH is low, the thyroid is likely producing too much T3/T4, raising the clinical suspicion for hyperthyroidism or secondary hypothyroidism. T4 can be measured as total T4 or free (FT4). Total T4 measures both the free and the bound hormone available, whereas FT4 assesses the T4 hormone that is freely circulating in the blood and available for use. FT4 is more commonly performed since it provides the best insight into the severity of an abnormal TSH level. FT4 is most accurate when performed in conjunction with a TSH level, so these tests are usually ordered together (ATA, 2019; BCGuidelines, 2018; Snyder, 2020b). 

A thyroid panel typically consists of three main tests: TSH, FT4, and free T3 (T3, Free) or total T3, as seen in Table 2 (American Board of Internal Medicine [ABIM], 2019). Free T3 is less reliable and not clinically indicated in suspected thyroid disease. The total T3 test is reserved for identifying hyperthyroidism or determining its severity, as patients with an overactive thyroid have elevated T3 levels. T3 testing is not clinically useful in hypothyroidism, as both TSH and FT4 are typically abnormal earlier in this condition than the T3 level. Even patients with severe hypothyroidism may present with a T3 level that is within normal limits (ATA, 2019). 

If not performed concurrently as a panel of tests, the TSH should be drawn first; if TSH is low or in the lower end of the normal range, an FT4 level should be drawn. With secondary hypothyroidism, the TSH level is typically normal or slightly decreased, and the T4 level often decreases (Ross, 2019b). The most common thyroid conditions classified by TSH and FT4 values are demonstrated in Table 3 (ATA, n.d.b).

A complete blood count (CBC) and metabolic profile should also be completed. Patients with hypothyroidism may exhibit:

  • anemia, especially macrocytic anemia;
  • dilutional hyponatremia;
  • hyperlipidemia; and
  • elevations of transaminases, creatinine kinase, and alkaline phosphates (Orlander, 2019; Ross, 2019b). 

An electrocardiogram (ECG) may be indicated and may demonstrate sinus bradycardia, flat or inverted T-waves, or low-voltage QRS complexes (ATA, n.d.a; Hopper, 2015). In addition, the adrenal function must be fully assessed via a fasting morning serum cortisol level, potentially requiring an ACTH stimulation test, prior to initiating corrective treatment for secondary hypothyroidism. Both conditions (central hypothyroidism and adrenal insufficiency) often occur simultaneously, and the correction of hypothyroidism without first initiating treatment for adrenal insufficiency may trigger a life-threatening adrenal crisis (Ross, 2019a). Thyroid scanning using technetium-99m or iodine-123 or an ultrasound can help provide information about the etiology of the disease (Daniel, 2017). 

Treatment. Treatment for most cases of hypothyroidism begins with a low dose of levothyroxine (Synthroid), which is a synthetic form of T4. The typical initial dose for an adult with mild to moderate hypothyroidism is 50-75 µg/day (Orlander, 2019). Dosing for secondary hypothyroidism is weight-based and adjusted to keep FT4 in the upper normal reference range per the treatment guidelines from the ATA (Snyder, 2019c). Most patients with minimal endogenous thyroid function require between 1.6 and 1.8 µg/kg of body weight, although there is some discrepancy about whether this should be calculated using actual or ideal body weight. Elderly patients and those with ischemic heart disease should be started with a quarter to half of the suggested adult starting dose and titrated in small increments every 4-6 weeks (Orlander, 2019). Treatment with glucocorticoids for adrenal insufficiency should be started before or concurrently with thyroid hormone replacement but not after (Snyder, 2019c).

The goal of treatment is to replace the hormone that is no longer being made by the thyroid. Clinical benefits should occur within 5 days of initiating the medication and level off in about 4 weeks (Orlander, 2019). As the patient’s T4 is being replaced by the levothyroxine (Synthroid), their FT4 level should gradually normalize. The FT4 and the patient’s report of symptoms should be the primary indicators for dose adjustments in central hypothyroidism, as the TSH level is not recommended for continuous monitoring of maintenance therapy. An FT4 level that is in the upper range of normal is considered ideal for patients with central hypothyroidism (Ross, 2019a). The primary danger of levothyroxine is taking too much or too little. If too much thyroid hormone is taken, signs and symptoms of hyperthyroidism will result. If too little is taken, the clinical manifestations of hypothyroidism will persist. During annual clinical evaluations, a patient on levothyroxine (Synthroid) therapy should be evaluated for the classic symptoms of hypothyroidism or hyperthyroidism (Orlander, 2019).

Patient education for hypothyroidism should include the following points:

  • Thyroid hormone replacement can increase the risk of bleeding with anticoagulation therapy; patients should be taught to monitor for signs and symptoms of bleeding and report any changes immediately.
  • Thyroid hormone replacement can interact with digoxin (Lanoxin); patients should monitor their pulse daily.
  • Patients should inform all providers of their condition and current medication list to avoid potential interactions with other medications or therapies. 
  • Patients should avoid the use of herbals or OTC medications without prior approval from their health care team, as they may alter the effects of their thyroid hormone therapy. 
  • Patients are encouraged to take good care of their skin; hypothyroidism patients typically report dry skin, which may lead to breakdown. They should avoid perfumed soaps or shower gels and moisturize daily with fragrance-free lotion. 
  • Patients should avoid commercial weight-loss products and maintain a well-balanced diet. Rapid weight loss is a sign of hyperthyroidism and may indicate overtreatment. 
  • Constipation is common with hypothyroidism, so a high-fiber diet with adequate fluid intake is essential (ATA, n.d.a). 

Complications. If not well managed, the potential complications of thyroid dysfunction include:

  • bleeding tendencies;
  • benign intracranial hypertension;
  • atherosclerosis, decreased peripheral circulation, ischemic heart disease, heart failure, cardiomegaly, or other cardiovascular conditions;
  • deafness;
  • infertility;
  • GI disturbances such as pernicious anemia, achlorhydria (lack of hydrochloric acid), megacolon (abnormal dilation of the colon), or GI obstruction;
  • iron-deficiency anemia;
  • psychiatric symptoms; and
  • myxedema coma (ATA, n.d.a; Hopper, 2015). 

Myxedema coma usually occurs in patients with long-standing or untreated hypothyroidism. The condition can be triggered by infection, trauma, or exposure to extreme cold. The patient will develop hypothermia (under 95F), bradypnea (decreased respiratory rate), lethargy, hypoglycemia, decreased cardiac output, and a decreased level of consciousness. Death can ensue as a result of cardiac or respiratory failure if untreated (Hopper, 2015). Additional testing to diagnose myxedema includes:

  • random serum cortisol to assess adrenal function (if this test is within the normal range, an ACTH stimulation test is needed to assess function),
  • serum sodium level (typically indicates hyponatremia with low serum osmolality),
  • serum creatinine level (usually elevated), and
  • serum glucose (expected hypoglycemia; Eledrisi, 2018). 

Diagnostic tools such as the one developed by Chiong and colleagues (2015) can be used to screen for myxedema coma. This tool uses six criteria, including:

  • HR,
  • temperature,
  • Glasgow coma scale score,
  • TSH level,
  • FT4, and
  • precipitating factors such as infection, medication noncompliance, furosemide (Lasix) use, cold exposure, hypoglycemia, GI bleeding, heart failure, hypercapnia, or cerebrovascular event (Chiong et al., 2015). 

By rapidly diagnosing myxedema coma, treatment can be expedited. Myxedema coma requires aggressive treatment due to its life-threatening nature. The ATA makes a strong recommendation based on low-quality evidence that parenteral glucocorticoid therapy should be given at stress doses for the initial treatment of myxedema coma, prior to levothyroxine (Synthroid) administration. Parenteral levothyroxine (Synthroid) is typically administered at a dose of 4 µg/kg of body weight, or approximately 200-400 µg, as a bolus. A single or divided dose may be given, depending on the patient’s risk of cardiac disease. Standard daily replacement doses of 1.6 µg/kg/d should be given after the initial bolus. This dosing should be decreased by 25% (1.2 µg/kg/d) if given via IV. Once the patient has improved clinically, they should receive oral doses of levothyroxine (Synthroid) according to their TSH/FT4 level. Additionally, liothyronine (Cytomel) may be given in addition to levothyroxine (Synthroid). A loading dose of 5-20 µg of liothyronine (Cytomel) should be given, followed by a maintenance dose of 2.5-10 µg every 8 hours; lower doses should be considered for smaller or older patients or those with a history of coronary artery disease or arrhythmias (Jonklaas et al., 2014). 

Gonadotropic Dysfunction

Amenorrhea, or the lack of menstruation in females, can either be defined as primary or secondary. Primary amenorrhea is defined as no menses by age 15, although it may also be diagnosed at age 13 in the context of no secondary sexual characteristics (Welt & Barbieri, 2020a). Secondary amenorrhea is clinically defined as a lack of menses for 3 or more months in a woman whose menstrual cycles were previously regular, or 6 or more months in a woman whose cycles were irregular previously (Shahid et al., 2020; Welt & Barbieri, 2020b).

Primary Hypogonadism

Primary hypogonadism refers to a pathology affecting the ovaries or testes themselves, not the entire hypothalamic-pituitary-gonadal (HPG) axis. In women, this may present as POI; in men, it may present as infertility. In either sex, primary hypogonadism may also involve delayed puberty. Delayed puberty is defined in the US as a lack of secondary sexual characteristics by the age of 12 in females and the age of 14 in males (Crowley & Pitteloud, 2018). The symptoms of hypogonadism are relatively consistent, whether the pathology is primary or secondary. Hypogonadism in females—primarily due to reduced estrogen and progesterone levels—typically presents with menstrual irregularities, including oligomenorrhea, amenorrhea, and anovulation. Reduced estrogen levels can also cause hot flashes, night sweats, insomnia, vaginal tissue atrophy, decreased libido, mood swings, dry skin, decreased BMD, and dyspareunia in women. Elevated levels of estrogen in females may lead to weight gain, dysmenorrhea (more painful menstruation), menorrhagia (heavier) or lighter menstrual periods, worsened mood swings, bloating, and breast tenderness immediately prior to menstruation (premenstrual syndrome, or PMS), fibrocystic breasts, uterine fibroid development, fatigue, decreased libido, and symptoms of depression or anxiety (El Sayed et al., 2020; Hormone Health Network [HHN], 2018, 2019; Shahid et al., 2020). Hypogonadism in men—typically related to testosterone deficiency—can lead to decreased libido, erectile dysfunction, decreased sperm count, and gynecomastia. It can cause reduced nocturnal penile tumescence (spontaneous nocturnal or morning erections), loss of body hair, decreased BMD, smaller testes, fatigue, depression, anemia, increased body fat, and reduced muscle mass. Chronically, low testosterone can lead to decreased bone density, decreased energy, and infertility. Elevated testosterone levels may lead to premature puberty in adolescents. Estrogen deficiency in males may prompt an increase in abdominal adiposity and decreased libido, while estrogen levels that are higher than expected in men may lead to gynecomastia, erectile dysfunction, and infertility (El Sayed et al., 2020; HHN, 2018, 2019, 2020; Shahid et al., 2020; Snyder, 2020d).

Pathophysiology. POI is characterized by ovarian failure with hypogonadism despite elevated levels of FSH. About 75-90% of cases are categorized as idiopathic with no known cause, while autoimmune disease accounts for roughly 4% of cases. Other less common causes of POI include iatrogenic injury (e.g., chemotherapy and radiation therapy), Turner syndrome, fragile X, and other genetic defects (Welt, 2018).

Primary hypogonadism in males damages the seminiferous tubules, making sperm production and fertility not possible (Snyder, 2019b). Potential causes of primary hypogonadism include genetic defects (Klinefelter syndrome), accidental testicular injury, or iatrogenic injury due to chemotherapy, radiation therapy, surgery, and infection (Surampudi et al., 2014).

Delayed puberty may be categorized as either primary or secondary. Primary (hypergonadotropic) hypogonadism accounts for 13% of delayed puberty cases. It may be due to Turner syndrome, Klinefelter syndrome, an autoimmune disorder, infection, cryptorchidism, deficiency of testosterone biosynthesis, or iatrogenic causes, such as chemotherapy or radiation treatment (Crowley & Pitteloud, 2018). Gonadal dysgenesis—a lack of gonadal development—is responsible for as much as 43% of primary amenorrhea cases; another 15% may be related to Mullerian agenesis, or a lack of vaginal development (Welt & Barbieri, 2020a).

Diagnosis. The signs and symptoms of primary hypogonadism, including POI, mirror those of other forms of hypogonadism due to estrogen, progesterone, and testosterone deficiency (Snyder, 2020a). A thorough history and physical exam should provide helpful information. The physical examination should include an evaluation of the anatomy of the uterus, cervix, and vagina. Notation should be made about whether a hymen is intact, whether a transverse vaginal septum can be seen/palpated, or whether there is evidence of vaginal agenesis. An ultrasound to identify normal anatomy further may be indicated. Breast development, height, weight, and pubic hair presence or distribution should be noted to establish an accurate Tanner stage for both male and female patients. Acne or hirsutism should be noted. Physical indications of Turner syndrome include a low hairline, a webbed neck, a shield chest, and widely spaced nipples (Welt & Barbieri, 2020a). POI typically manifests before the age of 40, differentiating itself from the natural course of menopause. In 50-75% of cases, intermittent ovarian function occurs, potentially leading to irregular menses (Welt, 2019). 

No additional laboratory testing is required for women presenting with regular menses. In cases of amenorrhea, a pregnancy test should be performed first to rule out the possibility of pregnancy. An estradiol level that is below the expected reference range, in combination with LH/FSH levels that are above expected, indicates primary hypogonadism. Providers may consider a progesterone trial to assess further, in which 10 mg of medroxyprogesterone acetate (Provera) is given daily for 10 days. For a patient with primary hypogonadism, the expected outcome is no menses, while a menstrual period triggered by the progesterone trial indicates a secondary form of hypogonadism (Corenblum, 2020; Fleseriu et al., 2016; Snyder, 2020a, 2020b). A lack of withdrawal bleeding after the progesterone trial may also indicate an outflow tract obstruction or endometrial scarring. To identify endometrial scarring, estrogen and progestin cycling (0.625 mg/d of conjugated estrogen for 35 days, along with 10 mg medroxyprogesterone acetate [Provera] on days 26-35) may be performed. The lack of withdrawal bleeding with this more-involved testing indicates endometrial scarring, which can be confirmed using hysteroscopy or hysterosalpingogram (Welt & Barbieri, 2020b). TSH and PRL levels should also be considered, especially in patients with amenorrhea, to rule out hyperprolactinemia and thyroid dysfunction (Welt, 2019; Welt & Barbieri, 2020a). Laboratory studies in patients with POI typically demonstrate an elevated FSH level. An FSH level in the postmenopausal range per the laboratory reference is diagnostic of overt POI, while an FSH level above 10-15 IU/L and serum estradiol of 80 pg/mL or greater indicate occult POI or a diminishing ovarian reserve (Welt, 2019). Due to the common comorbidity of POI with adrenal dysfunction and thyroid dysfunction, both conditions should be established initially and rechecked annually using 0800 fasting cortisol and TSH (Welt, 2020). If a patient presents with primary amenorrhea, age-appropriate secondary sexual characteristics, and normal hormone levels, then an ultrasound or MRI should be ordered to assess for retained blood in the uterus, indicating an obstructed outflow tract. Other etiologies that should be considered include constitutional delay of growth and puberty (CDGP, discussed in the later section on secondary hypogonadism), polycystic ovary syndrome (PCOS, serum testosterone level should be checked if not already done), hyperprolactinemia (PRL should be checked to rule this out), and thyroid (TSH and FT4) dysfunction (Welt & Barbieri, 2020a).

Physical examination in males should note the penile and testicular anatomy, size, and any abnormal findings, especially signs of hypogonadism. Testing in males should be performed in the absence of acute/subacute illness and before 10 a.m. following an overnight fast. A reduced serum testosterone level confirms hypogonadism in males, while an elevated LH indicates primary hypogonadism. Most experts suggest repeating serum testosterone testing two or three times to ensure accuracy, with a reference range in most labs of 300-800 ng/dL. A sperm analysis may be warranted if there are fertility questions, as well as a serum PRL level (Corenblum, 2020; Fleseriu et al., 2016; Snyder, 2020a, 2020b, 2020d).

The primary presenting signs of delayed puberty among both males and females involve a lack of secondary sexual characteristics. Recommended laboratory tests include testosterone (males), estradiol (females), LH, FSH, PRL, TSH, and FT4. Tests should be performed before 10 a.m. after an overnight fast. Additional tests that may prove helpful in assessing these patients include a CBC, an erythrocyte sedimentation rate, liver function tests, celiac disease screening, iron studies, and a genetic karyotype (Crowley & Pitteloud, 2018). As previously stated, an abnormally low estradiol level in a female patient in combination with an elevated LH/FSH level indicates primary hypogonadism. A reduced serum testosterone level confirms hypogonadism in men; an elevated LH indicates primary hypogonadism (Snyder, 2020b).

Treatment. Estrogen replacement in POI patients has been shown to reduce the risk of osteopenia and cardiovascular disease and relieve the symptoms of urogenital atrophy. As with other forms of hypogonadism, treatment varies by age and fertility concerns. Younger girls (ages 11-12) should be started on a low-dose estrogen 17-beta transdermal patch (Vivelle). A 25-µg patch can be cut into quarters initially for an effective dose of 6.25 µg/day. The patch should be changed twice weekly per the manufacturer's recommendations, and this dose is typically maintained for 6 months. The dosage should then be increased by 6.25 µg/day every 6 months. After 24 months, once the patient is comfortably tolerating a full 25-µg patch, and if breast development is complete, 200 mg of cyclic micronized progesterone (Prometrium) can be added on menstrual cycle days 1-12. The treatment of secondary amenorrhea due to POI differs slightly. If seeking fertility, these patients should be counseled that only 5-10% of patients with POI achieve pregnancy, and this is not the primary goal of treatment. They can be started on 100 mcg/day of estradiol, given either transdermal via a patch (Vivelle) or the vaginal ring (NuvaRing). If the uterus remains intact, progesterone should be administered to avoid endometrial hyperplasia. As explained above, 200 mg of cyclic micronized progesterone (Prometrium) or 5-10 mg of medroxyprogesterone acetate (Provera) can be added on cycle days 1-12. Clomiphene citrate (Clomid) and/or gonadotropin treatment is rarely effective in female patients with POI seeking fertility. If fertility is not achieved with this regimen, in-vitro fertilization procedures with a donor oocyte or a donor embryo can be discussed or explored. In patients with secondary amenorrhea who are not seeking fertility, a combined oral contraceptive (ethinyl estradiol and progestin [Loestrin]) of choice can be utilized. Per recommendations from the American College of Obstetricians and Gynecologists, treatment should continue until age 50 or 51. Androgen replacement is not required for females with POI, assuming adrenal function remains intact (Welt, 2020). Women with endometrial adhesions should be referred for lysis of the adhesions followed by exogenous estrogen therapy to stimulate endometrial tissue regrowth (Welt & Barbieri, 2020b).

The goal of treatment for men with primary infertility does not involve reestablishing spermatogenesis, as this is often not possible. However, treatment may provide the benefits of virilization, improved sexual function, increased muscle mass, decreased body fat, improved BMD, and potentially improved mood, although this final benefit remains uncertain. Testosterone replacement may increase the patient's cardiovascular risk slightly, but this is unclear currently. Testosterone is the primary treatment option for primary hypogonadism in men, as it is easy to obtain and less expensive than human chorionic gonadotropin (hCG). Unfortunately, the rapid metabolism of testosterone by the liver precludes PO administration. For this reason, testosterone is typically administered transdermally or parenterally. Gel products tend to be more expensive than injectable esters but provide less fluctuation in serum testosterone levels. Current topical options in the US include three gel preparations of testosterone (Androgel 1% or 1.6%, Testim 1%, and Fortesta 2%) and one solution (Axiron 2%). All must be applied daily to varying locations (Fortesta to the thighs, Axiron to the axilla). Patients using Androgel should be cautioned regarding skin irritation, although this has been reported with all topical formulas. Patients who are prescribed Testim may report an unpleasant odor. All topical applications carry a risk of transferring the medication to family members and other close contacts. This may pose a significant risk for pregnant partners or infants and small children. Patients should be instructed to practice diligent hand hygiene after applying the medication, allow the medication to dry fully after application, and avoid getting the medicated body part wet for at least 5 hours after application (Snyder, 2020d; Surampudi et al., 2014). 

A testosterone patch (Androderm) is also available at 2 mg and 4 mg and should be applied daily to the arms or torso. Unfortunately, up to 30% of users report a severe skin rash with this option. Injectable options in the US include testosterone enanthate (Delatestryl), which is administered intramuscularly (IM) every 1-2 weeks. Testosterone cypionate (Depo-Testosterone) may be easier for providers and patients to access. Testosterone undecanoate (Aveed) is injected via deep IM (gluteus) less frequently (second dose at week 4, subsequent doses every 10 weeks thereafter). This version is difficult to access and is currently being monitored by the federal Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of pulmonary oil microembolism and anaphylaxis. For this reason, authorized prescribers are limited, and patients must be fully educated regarding the risks prior to administration. Patients must be monitored closely for 30 minutes following administration (Snyder, 2020d; Surampudi et al., 2014). 

A weekly SQ injectable testosterone enanthate (Xyosted) was approved for use in the US in recent years, but clinically it is not used frequently due to insufficient evidence regarding its safety and efficacy at this time. Some oral preparations are 17-alpha alkylated to slow metabolism by the liver, but most options produce less-potent virilization results than other available preparations and are more likely to cause hepatic dysfunction. A buccal testosterone tablet (Striant SR) is dosed BID and meant to be dissolved along the upper anterior gum line. Implantable SQ pellets of testosterone (Testopel) are implanted in the subcutaneous tissue of the buttocks, abdomen, or thigh every 3-6 months. Patients should be warned of the risks of extrusion, infection, or fibrosis when using implantable pellets. A nasal spray preparation of testosterone (Natesto) is also available in the US. It should be dosed TID, which may decrease patient compliance but carries less risk of treatment transfer to close contacts. Most users (73%) report rhinorrhea, epistaxis, sinusitis, or nasal scabbing. Any formulation of testosterone can cause acne, gynecomastia, weight gain, fluid retention, increased HDL, benign prostatic hyperplasia, increased hemoglobin/hematocrit/red blood cells, and sleep apnea. Testosterone may also increase the risk of prostate cancer, and treatment is contraindicated in those with a history of prostate or breast cancer (Snyder, 2020d; Surampudi et al., 2014). 

Screening for prostate cancer among patients on testosterone therapy should begin at age 50 (40 if considered at increased risk) at 3 months, at 1 year, and then per the standard of care for healthy men. Testosterone treatment is contraindicated for patients with lower urinary tract symptoms, erythrocytosis (hematocrit above 50%), severe untreated sleep apnea, or uncontrolled congestive heart failure. Testosterone and LH levels should be monitored 2-3 months after starting therapy and following any dosage adjustments, with a goal of serum testosterone between 500 and 600 ng/dL. Once the patient levels are stable, these laboratory tests should be rechecked every 6-12 months. For men using injectable testosterone, serum testosterone/LH levels should be drawn midway between injections. Hematocrit should be checked 3 months after starting therapy and yearly thereafter, and BMD should be assessed every 2 years. Injectable hCG is not used for the treatment of primary hypogonadism but is discussed in greater detail in the forthcoming section on the treatment of secondary hypogonadism in men seeking fertility (Snyder, 2020d; Surampudi et al., 2014).

The treatment of females with delayed puberty should follow the recommendations for POI in young girls with primary amenorrhea; if required, their treatment should gradually transition to adult dosages as above. Young males should be treated with testosterone, which is typically dosed as 50 mg of testosterone enanthate (Delatestryl) or cypionate (Depo-Testosterone) monthly. In the US, testosterone gels are not approved for use in patients under the age of 18, and there are no oral preparations available for this age group. If long-term treatment is required for male patients, treatment with testosterone is most common, as fertility is not a treatment goal among these patients (Crowley & Pitteloud, 2018).


Secondary Hypogonadism

Secondary hypogonadism—also referred to as central or hypogonadotropic hypogonadism—is a lack of LH and FSH production by the anterior pituitary, which leads to deficiencies in estrogen, progesterone, and/or testosterone (Snyder, 2020a).

Pathophysiology. The underlying causes of secondary hypogonadism mirror those previously listed for other forms of hypopituitarism (Snyder, 2019a). These can include infection, infiltrative disease, tumor, radiation therapy, traumatic injury, empty sella, or infarct/apoplexy. Hyperprolactinemia may also cause amenorrhea that is either primary or secondary (Welt & Barbieri, 2020a). 

Functional hypothalamic amenorrhea (FHA) is a form of secondary hypogonadism caused by hypothalamic dysfunction; it is believed to be responsible for approximately 35% of all cases of secondary amenorrhea and 2% of cases of primary amenorrhea. FHA is characterized by a reduction in the secretion of GnRH, which thereby diminishes the secretion of LH and FSH by the anterior pituitary and the secretion of estrogen and progesterone by the ovaries. Additionally, it may cause a reduction in IGF-1 and an increase in cortisol levels; this is potentially due to a diversion of limited energy resources to systems that are prioritized over the reproductive system (Shahid et al., 2020).

Secondary, or hypogonadotropic hypogonadism, accounts for the vast majority of delayed puberty cases. CDGP is the underlying cause in 53% of cases of secondary hypogonadism in children and adolescents, while 19% of cases are due to FHA. The remaining 12% of cases are due to other less-common etiologies, including isolated GnRH deficiency. CDGP is a familial disorder defined as a transient functional defect in GnRH secretion by the hypothalamus, and most cases are temporary and resolve spontaneously with time and treatment. In contrast, only 10% of isolated cases of GnRH deficiency resolve spontaneously (Crowley & Pitteloud, 2018).

Diagnosis. The signs and symptoms of secondary hypogonadism mirror those of other forms of hypogonadism due to estrogen, progesterone, and testosterone deficiency related to any cause (Snyder, 2020a). Other indications of hypothalamus or pituitary dysfunction include HA, visual changes, fatigue, polyuria, and polydipsia. A thorough history may indicate the underlying pathology responsible for hypogonadism. For example, a history of neonatal crisis may indicate congenital adrenal hyperplasia; poor childhood health may implicate hypothalamic/pituitary disease; acne and hirsutism may indicate PCOS; recent stress, a change in diet, or a change in exercise routine may indicate FHA; and galactorrhea may indicate hyperprolactinemia. Finally, illicit drug use—especially heroin and methadone—may lead to amenorrhea in chronic users (Welt & Barbieri, 2020a). Risk factors for FHA include decreased body weight (BMI below 18), anorexia nervosa, excessive exercise, and emotional distress, all of which typically lead to an imbalance in energy intake and output, creating a prolonged energy deficit. In addition to amenorrhea, patients with FHA will typically exhibit decreased BMD, mood disorders, and other signs of estrogen deficiency like breast tissue and vaginal atrophy, and dyspareunia or other indications of sexual dysfunction (Shahid et al., 2020).

No testing is required for women presenting with regular menses, and a pregnancy test should be done to rule out the possibility of pregnancy first. Other causes of menstrual irregularities related to impaired ovulation (hyperprolactinemia, hyperandrogenism, and thyroid disease) should be ruled out, particularly if no other pituitary hormone deficits are evident. Estradiol, LH, and FSH levels that are all below the expected reference ranges indicate secondary hypogonadism. Providers may consider a progesterone (Prometrium) trial to assess the patient further. A menstrual period triggered by the progesterone trial indicates a secondary form of hypogonadism with endogenous estrogen exposure (Corenblum, 2020; Fleseriu et al., 2016; Snyder, 2020a, 2020b). A lack of withdrawal bleeding after the progesterone trial indicates hypoestrogenism or an outflow tract obstruction (Welt & Barbieri, 2020b). Decreased estradiol and LH with an FSH level that is at the lower end of normal typically indicate FHA (Welt & Barbieri, 2020a). 

Testing for central hypogonadism should occur in the absence of acute/subacute illness and before 10 a.m. following an overnight fast. In males, a reduced serum testosterone level confirms hypogonadism, and a reduced or normal LH indicates secondary hypogonadism. A sperm analysis may be warranted if there are fertility concerns, as well as a serum PRL level (Corenblum, 2020; Fleseriu et al., 2016; Snyder, 2020a, 2020b).

Bone age should be assessed in those diagnosed with delayed puberty, as patients with CDGP typically present with a bone age that is 20% younger than their chronological age. MRI may help assess for any space-occupying lesions that could be disrupting the patient's normal endocrine function (Crowley & Pitteloud, 2018).

Treatment. FHA should be treated using a multidisciplinary approach, including behavioral therapy with psychological and/or psychiatric support if appropriate. Treatment goals should include weight gain and stress reduction. If FHA exists without an eating disorder diagnosis, the patient should be further evaluated for possible DM or celiac disease. Patients with congenital GnRH deficiency should be referred to an endocrine practice with experience managing this condition but are typically treated using exogenous gonadotropins or pulsatile GnRH (not currently available in the US commercially, only as a research-based therapy). These patients should also be referred to a reproductive endocrinologist if fertility is desired (Welt & Barbieri, 2020a, 2020b).

Treatment for secondary hypogonadism varies based on sex and the fertility concerns of the patient. Premenopausal females who are not seeking fertility should be treated with a combination of transdermal estradiol (Vivelle) daily with progesterone (Prometrium, Provera) on cycle days 1-12. Alternatively, transdermal estradiol (Vivelle) on cycle days 1-25 with progesterone (Prometrium, Provera) on days 16-25 may also be used. If the patient reports extreme PMS, estrogen with a lower dose of progesterone (Prometrium, Provera) can be prescribed daily. Premenopausal females who are seeking fertility should be treated with gonadotropins, LH, and FSH (Novarel, Menopur) via injection, the details of which are outside the scope of this activity. Postmenopausal females should be treated symptomatically only with estradiol and progestin (Premarin; Snyder, 2019c). Androgen—including testosterone—replacement in women with hypogonadism is not recommended (Welt, 2020).

Males who are not seeking fertility can be treated with exogenous testosterone (Androderm [transdermal patch], AndroGel [transdermal gel], or Depo-Testosterone [injection]) using the same treatment algorithm as described above for primary hypogonadism. Males seeking fertility should be treated with gonadotropins for pituitary disease or GnRH or gonadotropins for hypothalamus disease (Mayo Clinic, 2020; Snyder, 2019c). Fertility restoration is more likely to be effective in males if their hypogonadism is mild to moderate, the condition began after puberty was completed, the patient has bilateral descended testicles, and the patient has a prior history of treatment with testosterone or gonadotropins. First-line treatment should include hCG (Novarel) to replace the deficient LH, as it is less expensive and more likely to be effective as a monotherapy compared to FSH. Recombinant hCG is not currently recommended. The non-recombinant formula is produced from the urine of pregnant women. It can be self-administered at a standard dose of 2,000 units IM three times/week. While SQ administration is preferred by patients, this method is not currently FDA-approved. Serum testosterone should be reassessed every 1-2 months, with a goal of 400-800 ng/dL (13.87-27.7 nmol/L). The dose may be increased every 2-3 months, as some patients require up to 10,000 units/dose. A patient with a poor response to therapy despite increasing dosages may have anti-hCG antibodies. If no improvement occurs with 10,000 units three times/week, the patient is unlikely to improve with higher doses, which pose a significantly increased risk of side effects. If the patient’s serum testosterone has been stable for at least 6 months, their sperm count should be assessed. If the resulting value is under 5 million/mL, the addition of human menopausal gonadotropin (hMG [Menopur]) to replace FSH should be considered. This is especially important for patients with a history of secondary hypogonadism with an onset prior to puberty or cryptorchidism. This should be dosed at 75 units IM three times/week and can be combined in the same syringe with hCG safely. Recombinant human FSH (rFSH [Gonal-f]) is available but at a significantly increased cost and similar effectiveness (with no head-to-head trials directly comparing the two), so its use is not currently recommended. The sperm count should be rechecked every 1-3 months. If the sperm count remains below 5 million/mL after 6 months of combined hCG/hMG treatment, the dose of hMG can be increased to 150 units IM three times/week. While the sperm count may rise as quickly as 6-10 months after starting treatment, pregnancy typically takes 21-38 months. Once pregnancy occurs, hCG (Novarel) should be continued if future pregnancies are desired, but hMG (Menopur) can be stopped temporarily due to cost and restarted in the future when desired. If no further pregnancies are desired, the patient can elect to continue hCG (Novarel) or transition to testosterone treatment. Alternative treatments that are appropriate for patients with hypothalamic deficiency only include pulsatile GnRH and clomiphene citrate (Clomid). Pulsatile GnRH has limited availability, involves a high cost, and requires an SQ infusion pump (similar to an insulin pump) with similar effectiveness, so this option is not often recommended. In the US, it is only available as a research-based therapy. Clomiphene citrate (Clomid) functions as a weak estrogen receptor antagonist, stimulating gonadotropin release by the pituitary, so it may be used (off-label) to increase testosterone and sperm count in men with hypothalamic disease (Snyder, 2019b). 

Treatment for patients with delayed puberty due to secondary hypogonadism mirrors the previously described treatments above for primary delayed puberty. Patients with CDGP may require two periods of treatment, each lasting 3-6 months, before the spontaneous return of endogenous hormonal secretion. Treatment can be withheld for 1-3 months to determine if spontaneous hormone production occurs. Conversely, if little to no sexual development happens following pharmacological treatment, then isolated GnRH is the most likely diagnosis. If long-term treatment is required for male patients, treatment with hCG [Novarel] is appropriate for those with secondary hypogonadism who are seeking fertility or testosterone for those not seeking fertility (Crowley & Pitteloud, 2018).

For learners who are eager to access additional content related to the endocrine system and endocrine disorders, please see the following NursingCE courses:

  • Endocrine and Hormonal Disorders Part 1: Anatomy and Physiology
  • Endocrine and Hormonal Disorders Part 3: Syndromes of Excessive Hormone Secretion
  • Endocrine and Hormonal Disorders Part 4: Adrenal Gland Disorders
  • Diabetes
  • Osteoporosis
  • Thyroid Dysfunction
  • Sexual Dysfunction


References

American Board of Internal Medicine. (2019). ABIM laboratory test reference ranges - January2019. https://www.abim.org/~/media/ABIM%20Public/Files/pdf/exam/laboratory-reference-ranges.pdf

American Thyroid Association. (n.d.a). Hypothyroidism (underactive). Retrieved July 16, 2020, from https://www.thyroid.org/hypothyroidism/

American Thyroid Association. (n.d.b). Thyroid function tests. Retrieved May 29, 2020, from https://www.thyroid.org/thyroid-function-tests/

American Thyroid Association. (2019). Thyroid function tests FAQ. https://www.thyroid.org/wp-content/uploads/patients/brochures/thyroid_function_tests_faq.pdf

BCGuidelines. (2018). Thyroid function testing in the diagnosis and monitoring of thyroid function disorder. https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/thyroid-function-testing.pdf

CFCF. (2014). Thyroid and parathyroid. [Image]. https://commons.wikimedia.org/wiki/File:Illu_thyroid_parathyroid.jpg

Chapman, I. M. (2019). Gigantism and acromegaly. In Merck Manual of diagnosis and therapy. Merck Sharp & Dohme. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/pituitary-disorders/gigantism-and-acromegaly. 

Chiong, Y. V., Bammerlin, E., & Mariash, C. N. (2015). Development of an objective tool for the diagnosis of myxedema coma. Translational Research, 166(3), 233-243. http://doi.org/10.1016/j.trsl.2015.01.003

Cleveland Clinic. (2020). Somatropin, rh-GH injection. https://my.clevelandclinic.org/health/drugs/19180-somatropin-rh-gh-injection

Corenblum, B. (2020). Hypopituitarism (panhypopituitarism). https://emedicine.medscape.com/article/122287-overview

Crowley, W. F., & Pitteloud, N. (2018). Approach to the patient with delayed puberty. UpToDate. https://www.uptodate.com/contents/approach-to-the-patient-with-delayed-puberty

Daniel, M. S. (2017). Congenital hypothyroidism. https://emedicine.medscape.com/article/919758-overview#a1

Duke Health. (2018). Thyroid disorders in children. https://www.dukehealth.org/pediatric-treatments/pediatric-endocrinology/thyroid-disorders-children

Eledrisi, M. S. (2018). Myxedema coma or crisis differential diagnoses. https://emedicine.medscape.com/article/123577-differential

El Sayed, S. A., Fahmy, M. W., & Schwartz, J. (2020). Physiology, pituitary gland. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459247/

Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016). Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline, The Journal of Clinical Endocrinology & Metabolism, 101(11), 3888–3921. https://doi.org/10.1210/jc.2016-2118

Gounden, V., & Jialal, I. (2020). Hypopituitarism (panhypopituitarism). StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470414/

Häggström, M. (2009). Thyroid hormones [image]. https://commons.wikimedia.org/wiki/File:Thyroid_system.svg

Hopper, P. D. (2015). Understanding medical-surgical nursing (5th ed.). FA Davis.

Hormone Health Network. (2018). Estrogen. https://www.hormone.org/your-health-and-hormones/glands-and-hormones-a-to-z/hormones/estrogen

Hormone Health Network. (2019). Pituitary gland. https://www.hormone.org/your-health-and-hormones/glands-and-hormones-a-to-z/glands/pituitary-gland

Hormone Health Network. (2020). Testosterone and androgens. https://www.hormone.org/your-health-and-hormones/glands-and-hormones-a-to-z/hormones/testosterone

Ignatavicius, D. D., Workman, M. L., Rebar, C. R., & Heimgartner, N. M. (2018). Medical-surgical nursing concepts for interprofessional collaborative care (9th ed.). Elsevier.

Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Francesco, S. C., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism. Thyroid, 24(12). https://doi.org/10.1089/thy.2014.0028

Khardori, R. (2020). Diabetes insipidus. https://emedicine.medscape.com/article/117648-overview 

Mayo Clinic. (2018). Dwarfism. https://www.mayoclinic.org/diseases-conditions/dwarfism/symptoms-causes/syc-20371969

Mayo Clinic. (2019a). Diabetes insipidus. https://www.mayoclinic.org/diseases-conditions/diabetes-insipidus/symptoms-causes/syc-20351269

Mayo Clinic. (2019b). Hypopituitarism. https://www.mayoclinic.org/diseases-conditions/hypopituitarism/symptoms-causes/syc-20351645

Mayo Clinic. (2020). Follicle-stimulating hormone and luteinizing hormone (intramuscular route, subcutaneous route). https://www.mayoclinic.org/drugs-supplements/follicle-stimulating-hormone-and-luteinizing-hormone-intramuscular-route-subcutaneous-route/description/drg-20062932

National Institute of Diabetes and Digestive and Kidney Diseases. (2015). Diabetes insipidus. https://www.niddk.nih.gov/health-information/kidney-disease/diabetes-insipidus

Nieman, L. K. (2020). Treatment of adrenal insufficiency in adults. UpToDate. https://www.uptodate.com/contents/treatment-of-adrenal-insufficiency-in-adults

OpenStax College. (2013). The endocrine system. [Image]. https://commons.wikimedia.org/wiki/File:1801_The_Endocrine_System.jpg

Orlander, P. R. (2019). Hypothyroidism. https://emedicine.medscape.com/article/122393-overview

Richmond, E. J., & Rogol, A. D. (2020a). Diagnosis of growth hormone deficiency in children. UpToDate. https://www.uptodate.com/contents/diagnosis-of-growth-hormone-deficiency-in-children

Richmond, E. J., & Rogol, A. D. (2020b). Diagnostic approach to children and adolescents with short stature. UpToDate. https://www.uptodate.com/contents/diagnostic-approach-to-children-and-adolescents-with-short-stature

Rogol, A. D., & Richmond, E. J. (2020). Treatment of growth hormone deficiency in children. UpToDate. https://www.uptodate.com/contents/treatment-of-growth-hormone-deficiency-in-children

Ross, D. S. (2019a). Central hypothyroidism. UpToDate. https://www.uptodate.com/contents/central-hypothyroidism

Ross, D. S. (2019b). Diagnosis of and screening for hypothyroidism in nonpregnant adults. UpToDate. https://www.uptodate.com/contents/diagnosis-of-and-screening-for-hypothyroidism-in-nonpregnant-adults

Shahid, Z., Asuka, E., & Singh, G. (2020). Physiology, hypothalamus. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK535380/

Snyder, P. J. (2019a). Causes of hypopituitarism. UpToDate. https://www.uptodate.com/contents/causes-of-hypopituitarism

Snyder, P. J. (2019b). Induction of fertility in men with secondary hypogonadism. UpToDate. https://www.uptodate.com/contents/induction-of-fertility-in-men-with-secondary-hypogonadism

Snyder, P. J. (2019c). Treatment of hypopituitarism. UpToDate. https://www.uptodate.com/contents/treatment-of-hypopituitarism

Snyder, P. J. (2020a). Clinical manifestations of hypopituitarism. UpToDate. https://www.uptodate.com/contents/clinical-manifestations-of-hypopituitarism

Snyder, P. J. (2020b). Diagnostic testing for hypopituitarism. UpToDate. https://www.uptodate.com/contents/diagnostic-testing-for-hypopituitarism

Snyder, P. J. (2020c). Growth hormone deficiency in adults. UpToDate. https://www.uptodate.com/contents/growth-hormone-deficiency-in-adults

Snyder, P. J. (2020d). Testosterone treatment of male hypogonadism. UpToDate. https://www.uptodate.com/contents/testosterone-treatment-of-male-hypogonadism

Society for Endocrinology. (2018). Pituitary apoplexy. https://www.yourhormones.info/endocrine-conditions/pituitary-apoplexy/

Surampudi, P., Swerdloff, R. S., & Wang, C. (2014). An update on male hypogonadism therapy. Expert Opinion on Pharmacotherapy, 15(9), 1247–1264. https://doi.org/10.1517/14656566.2014.913022

US Preventive Services Task Force. (2015). Screening for thyroid dysfunction: Recommendation statement. American Family Physician, 91(11), 790A-790F. https://www.aafp.org/afp/2015/0601/od1.pdf

Welt, C. K. (2018). Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure). UpToDate. https://www.uptodate.com/contents/pathogenesis-and-causes-of-spontaneous-primary-ovarian-insufficiency-premature-ovarian-failure

Welt, C. K. (2019). Clinical manifestations and diagnosis of spontaneous primary ovarian insufficiency (premature ovarian failure). UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-spontaneous-primary-ovarian-insufficiency-premature-ovarian-failure

Welt, C. K. (2020). Management of spontaneous primary ovarian insufficiency (premature ovarian failure). UpToDate. https://www.uptodate.com/contents/management-of-spontaneous-primary-ovarian-insufficiency-premature-ovarian-failure

Welt, C. K., & Barbieri, R. L (2020a). Evaluation and management of primary amenorrhea. UpToDate. https://www.uptodate.com/contents/evaluation-and-management-of-primary-amenorrhea

Welt, C. K., & Barbieri, R. L (2020b). Evaluation and management of secondary amenorrhea. UpToDate. https://www.uptodate.com/contents/evaluation-and-management-of-secondary-amenorrhea

Willis, L. M. (2019). Professional guide to diseases (11th ed.). Wolters Kluwer.